Although AFP, AFP-L3, and DCP profiles have been intimately linked with aggressive HCC biology over the past three decades, most of these studies have focused on very early (BCLC-0), resectable HCC and palliative management of intermediate–advanced (BCLC C-D) HCC. This evidence concerns the gene ACE and hepatocellular carcinoma.